Wednesday, October 10, 2018 8:15:37 PM
First commercial-scale production and material revenues to commence from
MXC Investigational Medicinal Product (IMP)
• MXC’s Medicinal Cannabis based IMP, CannEpilTM is now available for supply in
Australia under the Authorised Prescriber Scheme
• Authorisation has been granted by the TGA to specialist prescribers who are now
authorised to supply CannEpilTM to patients in Australia
• Authorisation follows recent Human Research Ethics Committee endorsement
from St Vincent’s Hospital Melbourne for the use of CannEpilTM in the treatment
of adult patients with drug-resistant epilepsy
• Represents a major milestone for MXC, validating and confirming its seed-topharma
strategy with the start of commercial supply of its first IMP offering
• The Company expects this to initially generate $1 million in annualised revenue
from the initial base of approximately 100 patients
• CannEpilTM is expected to be available for supply in Australia by December 2018
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM